Pompe Disease Clinical Trial
Official title:
Evaluation of Respiratory and Skeletal Muscle Functions in Response to Acetylcholinesterase Inhibitors in Pompe Disease
Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the
neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant
treatment for people with Pompe disease, as it increases the functional impact of this
neurotransmitter.
Hypothesis: the use of pyridostigmine in Pompe disease will improve transmission of
acetylcholine across the neuromuscular junction, skeletal muscle function, respiratory
function, and quality of life.
Pompe is a rare disease, which occurs in approximately 1 per 40,000 births. It is a
progressive and often fatal neuromuscular disorder resulting from mutation in the gene for
acid alpha-glucosidase (GAA), an enzyme necessary to degrade glycogen. Accumulation of
glycogen in multiple tissues results in cardiac, respiratory and skeletal muscle dysfunction.
Enzyme replacement therapy (ERT) is currently the only treatment available, and although it
prolongs survival, adjuvant therapies are needed to help alleviate the dire symptoms of Pompe
disease.
Recent data has revealed that degradation of the neuromuscular junction (NMJ) occurs in Pompe
disease. Acetylcholinesterase inhibitors (AChEI) are substances that inhibit the AChE enzyme
from degrading acetylcholine at the NMJ, and thus increase the functional impact of this
neurotransmitter. AChEI are established as a beneficial therapy for individuals with primary
diseases of the NMJ, such as myasthenia gravis. Recently, administration of an AChEI was
demonstrated to improve NMJ pathology in both mice and individuals affected by other
congenital myopathies, including autosomal centronuclear myopathies (CNM), X-linked
myotubular myopathy (XLMTM) and mutation of tropomyosin 3 (TPM3). Specifically, both NMJ
transmission and motor function were improved. These studies demonstrate that AChEI can be
beneficial in myopathy associated with NMJ pathology.
In this study, we will study the acute effects of pyridostigmine on neuromuscular
transmission, as well as the prolonged effects on respiratory function, skeletal muscle
function and quality of life over a 90 day treatment period.
This project focuses on developing an adjuvant treatment to ERT that targets dysfunction at
the NMJ. Our ultimate goal is to reduce the deleterious consequences of Pompe disease and
improve the overall quality and duration of life in affected individuals.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01942590 -
Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT01409486 -
Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry
|
N/A | |
| Completed |
NCT00976352 -
Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01665326 -
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
|
||
| Completed |
NCT01758354 -
Newborn Screening Assay of Pompe's Disease
|
N/A | |
| Recruiting |
NCT00231400 -
Pompe Disease Registry Protocol
|
||
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Recruiting |
NCT04476550 -
Clinical Specimen Collection From Pompe Disease Patients
|
||
| Completed |
NCT01380743 -
Drug-drug Interaction Study
|
Phase 2 | |
| Recruiting |
NCT05734521 -
Avalglucosidase Alfa Pregnancy Study
|
||
| Completed |
NCT02742298 -
Pompe Disease QMUS and EIM
|
N/A | |
| Terminated |
NCT02185651 -
A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
|
Phase 1 | |
| Completed |
NCT02654886 -
Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.
|
N/A | |
| Completed |
NCT02405598 -
Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
|
Phase 4 | |
| Completed |
NCT00701129 -
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
|
Phase 4 | |
| Completed |
NCT01451879 -
Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
|
N/A | |
| Completed |
NCT02240407 -
Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease
|
Phase 1 | |
| Completed |
NCT05073783 -
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
|
||
| Active, not recruiting |
NCT04093349 -
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
|
Phase 1/Phase 2 | |
| Completed |
NCT02363153 -
Diet and Exercise in Pompe Disease
|
N/A |